Cardiovascular disease

TEA: Richest in Flavan-3-ols Says First Ever Dietary Recommendations for Bioactives

Retrieved on: 
Wednesday, November 16, 2022

This study points to an evolving body of research which suggests that "dietary bioactives play a key role in human health maintenance as well as disease prevention and mitigation".

Key Points: 
  • This study points to an evolving body of research which suggests that "dietary bioactives play a key role in human health maintenance as well as disease prevention and mitigation".
  • The recommended 400-600mg/day of flavan-3-ols from the study can be found in a variety of foods, the highest source being tea.
  • We know that living a healthy life should include being active and consuming both nutrients and bioactives.
  • The Tea and Herbal Association encourages tea drinking as a part of healthy living and supports the inclusion of bioactives to dietary recommendations for the improvement of health.

NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Preferred Therapy for High Risk Cardiovascular Disease

Retrieved on: 
Wednesday, November 23, 2022

-- Ordinary shares and warrants to commence trading on the Nasdaq Capital Market under the ticker symbols “NAMS” and “NAMSW,” respectively on November 23 –

Key Points: 
  • BROADWAY is a Phase 3 trial designed to evaluate the effect of obicetrapib on top of maximally tolerated lipid-lowering therapy in patients with established atherosclerotic cardiovascular disease.
  • PREVAIL is a cardiovascular outcomes trial in patients with a history of atherosclerotic cardiovascular disease with inadequately controlled LDL-C despite treatment with maximally tolerated lipid-modifying therapies.
  • The Company expects to announce data from both BROADWAY and BROOKLYN in 2024, and from the PREVAIL CVOT study in 2026.
  • Neither the Company nor any of its affiliates undertake any obligation to update these forward-looking statements, except as required by law.

G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements

Retrieved on: 
Tuesday, November 22, 2022

In accordance with Nasdaq Rule 5810(c)(2)(A), the Company has 45 calendar days, or until January 6, 2023, to submit a plan to regain compliance.

Key Points: 
  • In accordance with Nasdaq Rule 5810(c)(2)(A), the Company has 45 calendar days, or until January 6, 2023, to submit a plan to regain compliance.
  • The Company intends to evaluate its courses of action and to timely submit a plan to Nasdaq to regain compliance with the Nasdaq minimum shareholders equity requirement.
  • About G Medical Innovations Holdings Ltd.
    G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms.
  • G Medical Innovations Holdings Ltd.

Shockwave Medical to Participate in the Piper Sandler 34th Annual Healthcare Conference

Retrieved on: 
Tuesday, November 22, 2022

SANTA CLARA, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company will be participating in the Piper Sandler 34th Annual Virtual Healthcare Conference, scheduled to be held from November 29 to December 1, 2022.

Key Points: 
  • SANTA CLARA, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company will be participating in the Piper Sandler 34th Annual Virtual Healthcare Conference, scheduled to be held from November 29 to December 1, 2022.
  • Shockwave management is scheduled for a live fireside chat on Wednesday, November 30, 2022, at 9:30 a.m. Eastern Time.
  • Interested parties may access a live and archived webcast of the event on the "Investors" section of the companys website at: https://ir.shockwavemedical.com .
  • Shockwave is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated.

G Medical Innovations Announces First Half 2022 Financial Results and Provides Business Update

Retrieved on: 
Friday, November 18, 2022

Irvine, CA, Nov. 18, 2022 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (G Medical or the Company), an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms, today announced its financial results and provided a business update for the six months ended June 30, 2022.

Key Points: 
  • Irvine, CA, Nov. 18, 2022 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (G Medical or the Company), an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms, today announced its financial results and provided a business update for the six months ended June 30, 2022.
  • Cash and cash equivalents as of June 30, 2022, were $1,509 thousand, compared to $6,034 thousand as of December 31, 2021.
  • About G Medical Innovations Holdings Ltd.
    G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms.
  • The Companys actual results and financial condition may differ materially from those indicated in the forward-looking statements.

ENDONOVO ANNOUNCES PLAN TO EXPLORE STRATEGIC ALTERNATIVES FOR ITS SOFPULSE® MEDICAL DEVICE ASSETS

Retrieved on: 
Thursday, November 17, 2022

Los Angeles, CA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced plans to explore strategic alternatives to maximize the shareholder value potential of its SofPulse Pulsed Electro Magnetic Frequency (PEMF) proprietary assets.

Key Points: 
  • Los Angeles, CA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced plans to explore strategic alternatives to maximize the shareholder value potential of its SofPulse Pulsed Electro Magnetic Frequency (PEMF) proprietary assets.
  • We are extremely confident that our revolutionary medical technology can achieve extensive global reach with an aggressive expansion through strategic relationships, he said.
  • Therefore, we are looking to partner with global participants in the medical device market to spur the expansion.
  • We expect such investment alternatives to include partnerships, joint ventures, distribution and licensing agreements for our breakthrough PEMF medical technology.

Study finds proteomic risk scores for cardiovascular disease from SomaSignal® Cardio DM™ tests could support physicians in managing patient outcomes

Retrieved on: 
Thursday, November 17, 2022

BOULDER, Colo., Nov. 17, 2022 (GLOBE NEWSWIRE) -- In an upcoming randomized, controlled study enrolling 248 physicians, researchers are measuring whether SomaLogics SomaSignal tests aid physicians in the risk stratification for cardiovascular disease of their patients.

Key Points: 
  • BOULDER, Colo., Nov. 17, 2022 (GLOBE NEWSWIRE) -- In an upcoming randomized, controlled study enrolling 248 physicians, researchers are measuring whether SomaLogics SomaSignal tests aid physicians in the risk stratification for cardiovascular disease of their patients.
  • A positive study provides clinicians with a better tooland one they are more likely to usewhen caring for their patients.
  • SomaSignal tests continue to improve our understanding of an individuals unique cardiac risk.
  • SomaLogics Cardio DM test , a version of the SomaSignal cardiovascular test, is currently being used in clinically focused partnerships with healthcare providers as part of the SomaSignal Proteomics for Precision Medicine Initiative.

Incannex Development Update for IHL-42X for Obstructive Sleep Apnoea (‘OSA’)

Retrieved on: 
Thursday, November 17, 2022

MELBOURNE, Australia, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that Incannex has initiated a BA/BE study and is targeting submission of an IND application with the FDA in Q1 2023.

Key Points: 
  • The design of the BA/BE study is consistent with FDA recommendations for BA/BE and specific advice received by Incannex in the pre-IND meeting.
  • In parallel with the BA/BE study, Incannex is preparing an IND application for submission to the FDA.
  • Once the IND is opened, it is continuously updated with research and development results for the purpose of ongoing assessment by the FDA.
  • It is estimated that the annual economic burden of undiagnosed sleep apnoea among U.S. adults is approximately US$149.6 billion per annum.

Shockwave Medical Publishes Inaugural ESG Report

Retrieved on: 
Wednesday, November 16, 2022

SANTA CLARA, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the publication of its inaugural Environmental, Social and Governance (ESG) report highlighting the companys corporate responsibility and sustainability initiatives.

Key Points: 
  • SANTA CLARA, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the publication of its inaugural Environmental, Social and Governance (ESG) report highlighting the companys corporate responsibility and sustainability initiatives.
  • Our entire global organization is committed to operating responsibly, sustainably, and transparently and I am impressed by how our teams across Shockwave have embraced the practices associated with ESG, said Doug Godshall, President and Chief Executive Officer of Shockwave Medical.
  • At the core of our values is helping people, and the efforts associated with ESG extend these values beyond Shockwave and IVL for calcified vessels and to the broader world around us.
  • Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated.

Verizon and Higi to extend community healthcare access and services

Retrieved on: 
Tuesday, November 15, 2022

The collaboration will prioritize solution delivery in service of community healthcare stakeholders seeking to scale digital and virtual care delivery offerings.

Key Points: 
  • The collaboration will prioritize solution delivery in service of community healthcare stakeholders seeking to scale digital and virtual care delivery offerings.
  • The Higi platform provides digital touch points that will further extend Verizons assets across and above the network in service of better healthcare delivery said Iris Meijer, SVP of Business Marketing and Revenue Operations, Verizon Business.
  • By bundling these core services, Verizon and Higi will help to improve the digital and virtual care experience through home-based virtual care delivery and health equity service delivery.
  • Our partnership with Verizon supercharges our platform touch points in the community and home to meet the needs of healthcare consumers and stakeholders alike says Jeff Bennett, CEO of Higi.